glp 1 drugs weight watchers Introducing the new Weight Watchers

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al

Inducible nitric oxide synthase: Regulation, structure, and inhibition

Regor Therapeutics RGT-075 RGT-075 is a once-daily oral small-molecule GLP-1 receptor full agonist being developed by Regor for the treatment of metabolic disorders such as type 2 diabetes mellitus, obesity, and overweight conditions linked with weight-related comorbidities

Telogen effluvium (TE) is a type of non-scarring, diffuse hair loss that occurs when a large number of hair follicles shift prematurely from the growth phase (anagen) to the resting phase (telogen)

Strategies for switching weight loss medications prevent gaps in treatment

Notable Series A funding efforts for new-to-the-scene biotechs with early phase assets include $410 million for Verdiva Bio in 2025 and $400 million for Kailera Therapeutics in late 2024